Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

10-09-2019 | Lung cancer | Video | Article

Researcher comment: Combining microRNAs and LDCT to assess lung cancer risk profiles

print
PRINT
insite
SEARCH

Ugo Pastorino discusses the bioMILD study, which investigates a lung cancer screening program that supplements low-dose computed tomography with a blood microRNA assay (3:09).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read more about the bioMILD study here

print
PRINT

Related content

12-09-2019 | Screening | Conference coverage | News

microRNA plus LDCT guides optimal lung cancer screening intensity

12-09-2019 | Screening | Video | Article

Researcher comment: ILST findings support novel eligibility criteria
Image Credits